A - Agilent Technologies Inc. (A) Q2 2024 Earnings Call Transcript
2024-05-29 20:35:24 ET
Agilent Technologies, Inc. (A)
Q2 2024 Results Conference Call
May 29, 2024 04:30 PM ET
Company Participants
Parmeet Ahuja - Investor Relations
Padraig McDonnell - President & Chief Executive Officer
Bob McMahon - Senior Vice President & Chief Financial Officer
Phil Binns - President of Agilent Life Sciences & Applied Markets Group
Simon May - President of the Agilent Diagnostics and Genomics Group
Angelica Riemann - President of Agilent CrossLab Group
Conference Call Participants
Matt Sykes - Goldman Sachs
Jack Meehan - Nephron Research
Patrick Donnelly - Citi
Vijay Kumar - Evercore ISI
Dan Brennan - TD Cowen
Rachel Vatnsdal - JPMorgan
Doug Schenkel - Wolfe Research
Michael Ryskin - Bank of America
Dan Arias - Stifel
Josh Waldman - Cleeland Research
Catherine Schulte - Baird
Paul Knight - KeyBanc
Presentation
Operator
Ladies and gentlemen, welcome to the Agilent Technologies Q2 2024 Earnings Call. My name is Regina, and I will be coordinating your call today. [Operator Instructions].
I will now hand you over to your host, Parmeet Ahuja, to begin. Please go ahead.
Parmeet Ahuja
Thank you, and welcome, everyone, to Agilent's conference call for the second quarter of fiscal year 2024. With me are Padraig McDonnell, Agilent President and CEO; and Bob McMahon, Agilent's Senior Vice President and CFO. Joining in the Q&A will be Phil Binns, President of the Agilent Life Sciences and Applied Markets Group; Simon May, our newly named President of the Agilent Diagnostics and Genomics Group; and Angelica Riemann, President of the Agilent CrossLab Group.
This presentation is being webcast live. The news release for our second quarter financial results, investor presentation and information to supplement today's discussion along with the recording of this webcast are available on our website at www.investor.agilent.com. Today's comments will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciliations on our website. Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year and references to revenue growth are on a core basis.
Core revenue growth excludes the impact of currency and any acquisitions and divestitures completed within the past 12 months. Guidance is based on forecasted exchange rates. As previously announced, beginning in the first quarter of fiscal 2024, we implemented certain changes to our segment reporting structure related to the move of our cell analysis business from LSAG into DGG. We have recast our historical segment information to reflect these changes. These changes have no impact on our company's consolidated financial statements.
During this call, we will also make forward-looking statements about the financial performance of the Company. These statements are subject to risks and uncertainties and are only valid as of today. The Company assumes no obligation to update them. Please look at the Company's recent SEC filings for a more complete picture of our risks and other factors.
And now, I'd like to turn the call over to Padraig.
Padraig McDonnell
Thanks, Parmeet. Good afternoon, everyone, and thank you for joining today's call. I want to begin by saying I'm incredibly honored to serve as CEO of this great company, and I'm thankful for the opportunity to lead such a talented team. I truly believe the Agilent team is second to none, and I'm energized about the future possibilities that lie ahead of us. I also want to take this time to welcome our new DGG President, Simon May to the Agilent team. Simon's diversified experience, strong technical skills and growth mindset will be a key asset in this role....
Agilent Technologies, Inc. (A) Q2 2024 Earnings Call Transcript